ClinicalTrials.gg
Active, not recruitingNCT04411654Updated Oct 22, 2026

Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)

A Phase 1/2 interventional study of LY3884961 and Methylprednisolone in Gaucher Disease, Type 2, sponsored by Prevail Therapeutics. Active, not recruiting at 6 sites in 2 countries. Open to participants aged 0 Months to 24 Months. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Prevail Therapeutics (part of Eli Lilly and Company) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
0 Months to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 92 studies in Gaucher Disease with a site in United States — 20 open to participants now, 27 under way, 2 of them phase 3. Gaucher Disease · United States.

Enrollment
46th of 51
7 · median 30
Started
2021
with 5 others
Phase 1/2
6 of 92
none open now
Primary completion
2027-02
later than 9 of 25 live
Registered
68th of 92
by date

Among the 92 studies in Gaucher Disease with a site in United States, this one is the 46th largest by enrollment of the 51 interventional ones that give a count, is one of 6 that started in 2021, is one of 6 in phase 1/2, reaches primary completion later than 9 of the 25 other live ones, and was the 68th registered.

Gaucher Disease

177 studies on the registry are indexed under Gaucher Disease; 41 are open to participants now.

Browse Gaucher Disease studies →

Open to participants now

20 of the 92 studies in Gaucher Disease with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Gaucher Disease studies recruiting now, 11 (42%) set no upper age limit and 11 (42%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 0 Months to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Gaucher Disease with a site in United States, or all of them as a file.
02

Study summary

J3Z-MC-OJAB is an open-label, Phase 1/2, multicenter study to evaluate the safety and efficacy of single-dose LY3884961 (formerly PR001) in infants diagnosed with Type 2 Gaucher disease (GD2). For each patient, the study will be approximately 5 years in duration. During the first 12 months after dosing, patients will be evaluated for the effects of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will be followed up for an additional 4 years to monitor safety and changes on selected biomarkers and clinical outcomes.

03

Conditions studied

  • Gaucher Disease, Type 2

Browse trials for

Keywords

  • Gaucher Disease
  • GD
  • Gaucher
  • Type 2 Gaucher
  • Neuronopathic Gaucher
  • nGD
  • AAV9
  • GBA
  • Gene Therapy
  • Glucocerebrosidase
  • GBA1 mutation
  • Infants
04

Who can participate

Ages eligible
0 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bi-allelic GBA1 mutations consistent with a diagnosis of GD2 confirmed by the central laboratory.
  • Clinical diagnosis of GD2
  • Parent/legal guardian is capable of providing signed ; including compliance with the requirements and restrictions listed in the informed consent form (ICF) in this protocol.
  • Patient has a parent/legal guardian able to participate in the study as a source of information on the patient's health status and cognitive and functional abilities (including providing input into the rating scales).

Exclusion criteria

Exclusion Criteria:

  • Significant CNS disease other than GD2 that may be a cause for the patient's symptoms or interfere with study objectives.
  • Achieved independent gait.
  • Severe peripheral symptoms of GD which, in the opinion of the Investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study.
  • Concomitant disease, condition, or treatment which, in the opinion of the Investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study.
  • Use of any substrate reduction therapy (SRT) for GD treatment.
  • Use of prohibited medications, herbals, or over-the-counter agents as listed in the protocol.
  • Any type of prior gene or cell therapy.
  • Use of systemic or therapy other than protocol-specified immunosuppression.
  • Participation in another drug or device study within the past 3 months.
  • Brain MRI (magnetic resonance imaging) and MRA (magnetic resonance angiography) showing abnormality deemed a to intracisternal injection.
  • Clinically significant laboratory test result abnormalities assessed at screening.
  • Contraindications or intolerance to radiographic visualization methods (e.g. MRI, MRA, CT), and intolerance to contrast agents used for MRI or CT scans.
  • Contraindications to general anesthesia or sedation.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Low Dose

    Genetic: LY3884961 · Drug: Methylprednisolone · Drug: Sirolimus · Drug: Prednisone

  • Experimental
    High Dose

    Genetic: LY3884961 · Drug: Methylprednisolone · Drug: Sirolimus · Drug: Prednisone

Interventions

  • GeneticLY3884961

    Participants will receive a single dose of LY3884961 administered intracisternally.

  • Single IV pulse administered as concomitant medication.

  • Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.

  • Administered orally as concomitant medication, followed by dose tapering.

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events leading to discontinuation

    Time frame: Year 5

  2. Immunogenicity of AAV9 and GCase in blood

    Time frame: Up to Year 2

  3. Immunogenicity of AAV9 and GCase in CSF

    Time frame: Up to Year 1

Secondary outcomes

  1. Time to death

    Time frame: Baseline until event or study completion, up to Year 5

  2. Time to clinical event

    Clinical event defined as tracheostomy/invasive ventilation, and/or percutaneous endoscopic gastrostomy (PEG) tube placement, and/or nasogastric (NG) tube placement

    Time frame: Baseline until event or study completion, up to Year 5

  3. Change in cognitive function

    Measured using Bayley Scales of Infant and Toddler Development (BSID-III)

    Time frame: Months 6,12 and up to Year 2

  4. Change in cognitive function

    Measured using Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV) as appropriate. (Not all patients begin the study at birth. Only patients who are age 36 months at the designated study visits will be assessed using this measure)

    Time frame: Study Month 12 and up to Study Year 2

  5. Change in motor skills

    Change from baseline in motor function using Gross Motor Function Measure (GMFM-88).

    Time frame: Months 6, 12 and up to Year 2

  6. Change in motor skills

    Change from baseline in motor function using the BSID-III.

    Time frame: Months 6, 12 and up to Year 2

  7. Change in Clinical Global Impressions (Severity)

    Change from baseline in the clinical severity of illness (CGI-Severity {CGI-S}).

    Time frame: Months 6, 12 and up to Year 2

  8. Clinical Global Impressions (Improvement)

    Clinical improvement from baseline (CGI-Improvement \[CGI-I\]).

    Time frame: Months 6, 12 and up to Year 2

  9. Change in adaptive behavior and functioning

    Change from baseline in adaptive functioning using the Vineland Adaptive Behavior Scale (VABS-2) (2nd edition)

    Time frame: Months 6 and 12 and up to Year 2

  10. Change in most troubling symptoms

    Change from baseline in the Visual Analog Scale for the Most Troubling Symptoms (VAS-MTS)

    Time frame: Months 6, 12 and up to Year 2

  11. Change in behavioral symptoms

    Change from baseline in the Child Behavior Checklist (CBCL)

    Time frame: Months 6, 12 and up to Year 2

  12. Change in GCase (glucocerebrosidase) enzyme activity levels in blood

    Time frame: Up to Year 5

  13. Change in GCase enzyme activity levels in CSF (cerebrospinal fluid)

    Time frame: Up to Year 3

  14. Change in glycolipid levels in blood

    Time frame: Up to Year 5

  15. Change in glycolipid levels in CSF

    Time frame: Up to Year 3

  16. Individual Vector Shedding data

    Time frame: Up to Year 5

07

Study locations

6 sites
  • UCSF Benioff Children's Hospital, 747 52nd St
    Oakland, California 94609, United States
  • University of Minnesota Masonic Children's Hospital, 2450 Riverside Avenue
    Minneapolis, Minnesota 55454, United States
  • NYU Medical Center, 305 Second Ave, Suite 16
    New York, New York 10003, United States
  • Children's Hospital of Pittsburgh, 4401 Penn Avenue
    Pittsburgh, Pennsylvania 15224, United States
  • Lysosomal & Rare Disorders Research and Treatment Center
    Fairfax, Virginia 22030, United States
  • Manchester Centre for Genomic Medicine, 6th Floor, St Mary's Hospital, Oxford Road
    Manchester, M13 9WL, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2021 (actual). Primary completion is estimated for Feb 2027, 68 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2020
First posted
Jun 2, 2020
StartActual
Jun 29, 2021
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04411654
Responsible party
Sponsor
First posted
Jun 2, 2020
Start date
Jun 29, 2021
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Hamzeh Migdadi, M.D.
study director · Prevail Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methylprednisolone · Sirolimus · Prednisone

Start the discussion